Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company advancing novel bispecific antibody therapies for cancer treatment. This news hub provides investors and industry professionals with timely updates on APVO's clinical developments, platform innovations, and strategic milestones.
Our curated collection features official press releases and verified news about the company's ADAPTIR platform progress, clinical trial results for candidates like mipletamig in AML, and regulatory updates. Users will find updates on financial filings, research collaborations, and therapeutic pipeline expansions across hematologic malignancies and solid tumors.
This resource serves as a centralized reference for tracking APVO's progress in developing targeted immunotherapies designed to improve treatment safety and efficacy. Content is organized chronologically with clear sourcing to ensure reliable tracking of the company's scientific advancements and corporate developments.
Bookmark this page for streamlined access to APVO's latest announcements, including trial initiations, data presentations at medical conferences, and partnership disclosures. Check regularly for updates on how the company's modular protein engineering approaches aim to address unmet needs in oncology care.
Applied Materials (AMAT) has announced it will release its fiscal second quarter 2025 financial results on May 15, 2025.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company, has completed its previously announced registered direct offering, raising $2.0 million through the sale of 2,324,000 shares of common stock at $0.862 per share.
The offering was conducted at-the-market under Nasdaq rules, with Roth Capital Partners serving as the exclusive placement agent. The company plans to utilize the net proceeds for continued clinical development of its product candidates, working capital, and general corporate purposes.
The offering was made through a shelf registration statement on Form S-3 (File No. 333-284969) previously filed with the SEC. Aptevo specializes in developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies.
Aptevo Therapeutics (Nasdaq: APVO), a clinical-stage biotechnology company specializing in immune-oncology therapeutics, has announced a $2.0 million registered direct offering of common stock. The company will sell 2,324,000 shares at $0.862 per share, with the offering expected to close around April 22, 2025.
Roth Capital Partners is serving as the exclusive placement agent. The proceeds will support clinical development of product candidates, working capital, and general corporate purposes. The offering is being conducted under an existing shelf registration statement on Form S-3 previously filed with the SEC.
Aptevo Therapeutics (Nasdaq: APVO) has closed its previously announced registered direct offering and concurrent private placement, raising gross proceeds of $2.1 million. The offering consisted of 1,764,710 common stock shares and warrants to purchase up to 3,529,420 shares at a combined price of $1.19 per share and accompanying warrant.
The warrants have an exercise price of $1.19 per share, will be exercisable upon stockholder approval, and expire 5 years from approval date. Roth Capital Partners served as the exclusive placement agent. The company plans to use proceeds for clinical development of product candidates, working capital, and general corporate purposes.
Additionally, Aptevo amended existing warrants from December 12, 2024, reducing their exercise price from $9.53 to $1.19 per share for up to 1,647,088 shares, subject to stockholder approval.
Aptevo Therapeutics (Nasdaq:APVO) has announced a $2.1 million registered direct offering and concurrent private placement priced at $1.19 per share. The offering includes 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 additional shares.
The warrants will have an exercise price of $1.19 per share, becoming exercisable upon shareholder approval and expiring 5 years from the initial exercise date. Roth Capital Partners is serving as the exclusive placement agent.
The company plans to use the proceeds for clinical development of product candidates, working capital, and general corporate purposes. Additionally, Aptevo will amend previously issued warrants from December 12, 2024, reducing their exercise price from $9.53 to $1.19 per share for 1,647,088 shares.
Aptevo Therapeutics (NASDAQ:APVO) reported positive interim results from its RAINIER dose optimization trial for mipletamig in treating frontline AML patients. Two additional patients achieved remission within 30 days of treatment, bringing the total success rate to 9 out of 10 frontline patients across two trials.
The triplet combination of mipletamig + venetoclax + azacitidine achieved a 90% overall remission rate in frontline patients, significantly outperforming the 66% benchmark for the doublet therapy (venetoclax + azacitidine). The complete remission rate of 70% also surpasses the 36% rate from the Viale-A Pivotal trial.
In Cohort 2, which uses an 18mcg dosage level, three patients have been evaluated: two achieved remission within 30 days, while one progressed and passed away for unrelated reasons. Notably, no Cytokine Release Syndrome has been observed in the RAINIER trial, and all patients who achieved remission remain in remission.
Aptevo Therapeutics (NASDAQ:APVO) has provided an overview of APVO603, a novel bispecific antibody in preclinical development for solid tumor treatment. The drug targets 4-1BB and OX40 receptors to enhance anti-tumor immune responses.
Preclinical studies demonstrate that APVO603:
- Enhances T cell and NK cell proliferation
- Maintains favorable safety profile
- Inhibits immune exhaustion
- Shows robust anti-tumor response
The company also updated on other pipeline developments:
- Mipletamig: Phase 1b/2 RAINIER trial showing 100% remission in Cohort 1 within 30 days
- ALG.APV-527: Phase 1 trial for solid tumors showing 59% stable disease rate in 17 evaluable patients
Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biotechnology company specializing in immuno-oncology therapeutics with proprietary ADAPTIR® and ADAPTIR-FLEX® platforms, has announced its participation in two major industry conferences this March.
The company will attend the 37th Annual Roth Conference from March 16-18, 2025, in Dana Point, CA, where they will engage in a fireside chat with analyst Jonathan Aschoff. The conference will feature one-on-one meetings, fireside chats, and industry panels, hosting executives from approximately 450 growth sector companies.
Additionally, Aptevo will participate in the Bio-Europe Springtime Partnering Event from March 17-19, 2025, in Milan, Italy. This event is expected to gather nearly 4,000 attendees, focusing on fostering relationships between biotechnology and biopharmaceutical companies.
Aptevo Therapeutics (Nasdaq:APVO) CEO Marvin White will be featured on Bloomberg TV's RedChip Small Stocks, Big Money™ show on February 15, 2025. The interview will highlight the company's progress in developing bispecific immuno-oncology therapeutics.
The company's lead candidate, Mipletamig (CD3 x CD123), targeting the $6.3B AML market, has shown promising results in clinical trials with over 100 patients. In the RAINIER dose optimization trial, 100% of patients achieved remission within 30 days of treatment.
Their second clinical candidate, ALG.APV-527 (5T4 x 4-1BB), targeting solid tumors, demonstrated stable disease in 59% of patients (10/17) in recent dose escalation trials, with some patients maintaining stability for up to 12 months. The company also has three preclinical candidates in development.
Aptevo Therapeutics (NASDAQ:APVO) reported significant clinical progress for 2024. In the RAINIER trial, testing mipletamig for frontline AML treatment, 100% of Cohort 1 patients achieved remission within 30 days, with one patient reaching MRD-negative status. The drug showed a favorable safety profile with cytokine release syndrome.
The company's ALG.APV-527 Phase 1 trial for solid tumors demonstrated promising results, with a 59% stable disease rate (10 out of 17 evaluable patients). Notable outcomes included a breast cancer patient maintaining stable disease for >12 months and a colon cancer patient with stable disease for >6 months. The treatment showed liver toxicity, a common side effect in similar therapies.
These results build upon previous successful trials, including a Phase 1b combination therapy trial where 100% of frontline patients achieved remission, and a Phase 1a monotherapy trial showing 36% of evaluable patients experienced significant leukemic blast reduction.
